| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.4 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.4 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.4 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.4 |